FINVAC Platform
Influenza, RSV, Tuberculosis, other respiratory pathogens
Pre-clinicalActive
Key Facts
Indication
Influenza, RSV, Tuberculosis, other respiratory pathogens
Phase
Pre-clinical
Status
Active
Company
About Rokote Laboratories
Rokote Laboratories is a private, pre-revenue biotech developing a novel intranasal vaccine platform. Its FINVAC technology uses an adenoviral vector backbone to create vaccines that target the nasal mucosa, aiming to block infection and transmission of respiratory viruses like SARS-CoV-2, influenza, and RSV. The company is currently in Phase I clinical development with its lead COVID-19 vaccine and is positioning its platform for pandemic preparedness and seasonal respiratory disease. Leadership combines expertise in virology, immunology, and clinical operations.
View full company profile